ES2193406T3 - Composiciones y metodos para mejorar la funcion intestinal. - Google Patents

Composiciones y metodos para mejorar la funcion intestinal.

Info

Publication number
ES2193406T3
ES2193406T3 ES97946986T ES97946986T ES2193406T3 ES 2193406 T3 ES2193406 T3 ES 2193406T3 ES 97946986 T ES97946986 T ES 97946986T ES 97946986 T ES97946986 T ES 97946986T ES 2193406 T3 ES2193406 T3 ES 2193406T3
Authority
ES
Spain
Prior art keywords
compositions
methods
lpg
intestinal function
improve intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97946986T
Other languages
English (en)
Inventor
Daniel J Drucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
Original Assignee
1149336 Ontario Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of ES2193406T3 publication Critical patent/ES2193406T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL GLP - 2 ESTIMULA EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL INTESTINO GRUESO, CUANDO SE ADMINISTRA JUNTO CON OTROS AGENTES. LA INVENCION PROPORCIONA COMPOSICIONES FARMACEUTICAS DE GLP - 2 CON AL MENOS OTRO AGENTE QUE AUMENTE LA ACTIVIDAD BIOLOGICA DEL GLP - 2, PROCEDIMIENTOS PARA FOMENTAR EL CRECIMIENTO DEL TEJIDO TANTO DEL INTESTINO DELGADO COMO DEL GRUESO, Y PARA MEJORAR LOS TRASTORNOS NUTRICIONALES O GASTROINTESTINALES, GRACIAS A UN AUMENTO DE LOS NIVELES SERICOS DE GLP - 2 Y AL MENOS OTRO AGENTE, DESCRIBIENDOSE TAMBIEN KITS PARA LLEVAR A LA PRACTICA LOS PROCEDIMIENTOS DE LA INVENCION.
ES97946986T 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal. Expired - Lifetime ES2193406T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/763,177 US5952301A (en) 1996-12-10 1996-12-10 Compositions and methods for enhancing intestinal function

Publications (1)

Publication Number Publication Date
ES2193406T3 true ES2193406T3 (es) 2003-11-01

Family

ID=25067085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97946986T Expired - Lifetime ES2193406T3 (es) 1996-12-10 1997-12-10 Composiciones y metodos para mejorar la funcion intestinal.

Country Status (10)

Country Link
US (1) US5952301A (es)
EP (1) EP0944396B1 (es)
AT (1) ATE233096T1 (es)
AU (1) AU5220098A (es)
CA (1) CA2274596C (es)
DE (1) DE69719360T2 (es)
DK (1) DK0944396T3 (es)
ES (1) ES2193406T3 (es)
PT (1) PT944396E (es)
WO (1) WO1998025644A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
EP2583675A1 (en) * 1998-02-02 2013-04-24 Trustees Of Tufts College Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism
WO1999058144A1 (en) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
GB9906715D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
EP1187619A1 (en) * 1999-05-25 2002-03-20 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
EP1806138A1 (en) * 1999-05-25 2007-07-11 Point Therapeutics, Inc. Anti-tumor agents comprising boroproline compounds
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
DE60037535D1 (de) * 1999-11-03 2008-01-31 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
WO2001032199A1 (en) 1999-11-05 2001-05-10 Rogoff Joseph A Secretin and secretin pharmaceuticals for treating lactose intolerance
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
CA2466870A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
CA2468192A1 (en) * 2001-11-26 2003-06-05 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PT1689757E (pt) * 2003-11-12 2014-12-09 Sino Med Internat Alliance Inc Compostos heterocíclicos de ácido borónico
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
BRPI0513384A (pt) * 2004-07-14 2008-05-06 Novartis Ag combinação de inibidores de dpp-iv e compostos que modulam receptores de 5-ht3 e/ou 5-ht4
ATE498631T1 (de) * 2005-05-04 2011-03-15 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
KR101527233B1 (ko) 2006-11-08 2015-06-08 질랜드 파마 에이/에스 선택적인 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
US20110295151A1 (en) * 2010-05-26 2011-12-01 Bakos Gregory J Enteroendocrine Manipulation for Metabolic Effect
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
ES2913946T3 (es) 2013-07-08 2022-06-06 The Univ Of Utah Research Foundation Péptido y su uso en el tratamiento de trastornos inflamatorios
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
CN106589110B (zh) * 2015-10-15 2020-01-17 上海迈迹生物医药科技有限公司 包含聚合物和glp-2衍生物的缀合物
DK3551651T3 (da) 2016-12-09 2024-05-13 Zealand Pharma As Acylerede glp-1/glp-2-dobbeltagonister

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174838T3 (es) * 1991-10-07 2002-11-16 Brigham & Womens Hospital Metodo para aumentar la absorcion del intestino.
NZ243071A (en) * 1992-06-08 1994-09-27 Kabi Pharmacia Ab Igf-2 (or analogue) compositions for pharmaceutical uses
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP2218734B1 (en) * 1996-04-12 2013-06-05 1149336 Ontario Inc. Glucagon-like peptide-2 analogs

Also Published As

Publication number Publication date
CA2274596C (en) 2004-11-09
EP0944396B1 (en) 2003-02-26
DE69719360D1 (de) 2003-04-03
DE69719360T2 (de) 2003-12-04
AU5220098A (en) 1998-07-03
US5952301A (en) 1999-09-14
WO1998025644A1 (en) 1998-06-18
PT944396E (pt) 2003-07-31
CA2274596A1 (en) 1998-06-18
EP0944396A1 (en) 1999-09-29
ATE233096T1 (de) 2003-03-15
DK0944396T3 (da) 2003-06-23

Similar Documents

Publication Publication Date Title
ES2193406T3 (es) Composiciones y metodos para mejorar la funcion intestinal.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
BR9910251A (pt) Estimulação hematopoiética
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
ES2175460T3 (es) Compuesto de lipoxinas y su utilizacion en el tratamiento de patologias con proliferacion celular.
EA199901107A1 (ru) Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты)
DK124091D0 (da) Farmaceutisk genprodukt
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
ES2181725T3 (es) Inhibidores de hiv proteasa.
BR0103256A (pt) Utilização de substâncias bioquìmicas para uma composição para a prevenção e tratamento de condições de saúde causadas por constrição de células de músculo liso em órgãos do corpo humano
ES2035847T3 (es) Un procedimiento para la elaboracion de una preparacion farmaceutica.
CR9879A (es) Moduladores de ccr5 (divisional de la solicitud n° 6392)
ES2153034T3 (es) Sistema de suministro en microparticulas.
CO4770978A1 (es) Empleo de epinastina para el tratamiento de dolores
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
BRPI0418157A (pt) terapêutica de tumores alogênicos
DE69625918D1 (de) Lang wirksames mittel zur rektalen verabreichung
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
DOP2002000369A (es) Composicion
ES2172558T3 (es) Lubricante compatible con radiaciones para dispositivos medicos.